Scienture Holdings vs China SXT Pharmaceuticals
China SXT Pharmaceuticals is the larger business, with $1.1m of revenue in fiscal 2026 against $431,609 for Scienture Holdings (2.6 times as much). Scienture Holdings grew faster (215.9% against -34.6%). China SXT Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -545.2% against -9618.0%. Scienture Holdings carries less debt relative to equity (2.9% against 3.4%).
| Latest fiscal year | Scienture HoldingsSCNX, 2025 | China SXT PharmaceuticalsSXTC, 2026 |
|---|---|---|
| Revenue | $431,609 | $1.1m |
| Revenue growth | 215.9% | -34.6% |
| Net income | −$41.5m | −$6.2m |
| Operating margin | -9867.9% | -625.9% |
| Net margin | -9618.0% | -545.2% |
| Return on equity | -55.6% | -27.5% |
| Free cash flow | −$13.4m | −$4.0m |
| Cash | $6.7m | $28.2m |
| Total debt | $2.0m | $999,565 |
| Debt to equity | 2.9% | 3.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $134m | $2.0m |
| Price vs our value range | — | — |
| Moat score | 29 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |